Sabiia Seb
PortuguêsEspañolEnglish
Embrapa
        Busca avançada

Botão Atualizar


Botão Atualizar

Ordenar por: 

RelevânciaAutorTítuloAnoImprime registros no formato resumido
Registros recuperados: 1
Primeira ... 1 ... Última
Imagem não selecionada

Imprime registro no formato completo
Complement dependent cytotoxicity activity of therapeutic antibody fragments is acquired by immunogenic glycan coupling ArchiMer
Courtois, Anthony; Gac Breton, Stephanie; Berthou, Christian; Guezennec, Jean; Bordron, Anne; Boisset, Claire.
Oligosaccharides are implicated in the development of the immune response notably in complement activation. Anti-tumoural immunotherapy by monoclonal antibodies (mAbs) offers some advantages to chemotherapy including cell targeting but some of them are inefficient to generate cytotoxicity dependent complement (CDC) known to be important in the antibody's efficacy. The aim of this study is to give a CDC activity of mAb by linkage of a complement activating oligosaccharide to this antibody via a hetero-bifunctional linker allowing control of the conjugation reaction. We worked on non Hodgkin Burkitt's lymphoma as cancer source, Fab fragments of rituximab devoid of complement activity as mAb and the trisaccharide Gal alpha(1 -> 3)Gal beta(1 -> 4)GlcNAc...
Tipo: Text Palavras-chave: Complement system Gal alpha(1 ->; 3)Gal epitope immunogenic oligosaccharide immunotherapy non-Hodgkin lymphoma xenoantigen.
Ano: 2012 URL: http://archimer.ifremer.fr/doc/00125/23599/21423.pdf
Registros recuperados: 1
Primeira ... 1 ... Última
 

Empresa Brasileira de Pesquisa Agropecuária - Embrapa
Todos os direitos reservados, conforme Lei n° 9.610
Política de Privacidade
Área restrita

Embrapa
Parque Estação Biológica - PqEB s/n°
Brasília, DF - Brasil - CEP 70770-901
Fone: (61) 3448-4433 - Fax: (61) 3448-4890 / 3448-4891 SAC: https://www.embrapa.br/fale-conosco

Valid HTML 4.01 Transitional